Privately-held Swiss biotech firm Novimmune has added two experienced pharma executives to its senior management team.
The Geneva-based company, which is focused on the discovery and development of antibody-based drugs, has appointed Sven Zimmermann as its chief financial officer (CFO) and Mylène Fleurant as global head of quality.
Novimmune chief executive Eduard Holdener said: “We continue to add capabilities to our strong and experienced management team to support our growth strategy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze